Consequences of severe asthma exacerbations

Purpose of review Asthma exacerbations are major factors in asthma morbidity and also have long-term consequences. Recent findings Asthma is characterized by an accelerated and progressive loss of lung function. Recent evidence has pointed to the frequency of exacerbations as being a significant contributor to a loss of lung function in asthma. Summary A consequence of asthma exacerbations is a greater loss of lung function. Airway inflammation is central to asthma severity and susceptibility for exacerbations. Evidence suggests that the increase in airway inflammation during an asthma exacerbation further compromised lung function. Treatment of severe asthma with Type (T)-2 directed biologics significantly prevents the frequency of exacerbations in severe asthma. Early indications also suggest that prevention of exacerbations by biologics may reduce a loss in lung function from exacerbations.

[1]  Trung Nghia Tran,et al.  Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study , 2022, Thorax.

[2]  Matthew C. Altman,et al.  Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial , 2022, The Lancet.

[3]  W. Busse,et al.  What has been learned by cytokine targeting of asthma? , 2022, The Journal of allergy and clinical immunology.

[4]  W. Busse,et al.  Holy Grail: the journey towards disease modification in asthma , 2022, European Respiratory Review.

[5]  E. Hoffman,et al.  Mucus Plugs Persist in Asthma and Changes in Mucus Plugs Associate with Changes in Airflow Over Time. , 2022, American journal of respiratory and critical care medicine.

[6]  G. Koppelman,et al.  Biologic Therapies for Severe Asthma. , 2022, The New England journal of medicine.

[7]  G. Canonica,et al.  Severe asthma: One disease and multiple definitions , 2021, The World Allergy Organization journal.

[8]  I. Pavord,et al.  Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. , 2021, The Lancet. Respiratory medicine.

[9]  I. Pavord,et al.  Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. , 2021, The Lancet. Respiratory medicine.

[10]  Scott R. Presnell,et al.  Endotype of Allergic Asthma with Airway Obstruction in Urban Children. , 2021, The Journal of allergy and clinical immunology.

[11]  H. Hammad,et al.  The basic immunology of asthma , 2021, Cell.

[12]  W. Calhoun,et al.  Response to Parenteral Triamcinolone in Severe Asthma: A Useful Induced Phenotype for Clinicians? , 2021, American journal of respiratory and critical care medicine.

[13]  E. Bleecker,et al.  Responsiveness to Parenteral Corticosteroids and Lung Function Trajectory in Adults with Moderate to Severe Asthma. , 2020, American journal of respiratory and critical care medicine.

[14]  D. Price,et al.  Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management , 2020, American journal of respiratory and critical care medicine.

[15]  I. Pavord,et al.  Asthma progression and mortality: the role of inhaled corticosteroids , 2019, European Respiratory Journal.

[16]  L. Borish,et al.  Rhinovirus and Asthma Exacerbations. , 2019, Immunology and allergy clinics of North America.

[17]  Scott R. Presnell,et al.  Transcriptome networks identify mechanisms of viral and nonviral asthma exacerbations in children , 2019, Nature Immunology.

[18]  P. Woodruff,et al.  A Transcriptomic Method to Determine Airway Immune Dysfunction in T2‐High and T2‐Low Asthma , 2019, American journal of respiratory and critical care medicine.

[19]  L. Wain,et al.  Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study , 2019, The Lancet. Respiratory medicine.

[20]  E. Bleecker,et al.  Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids , 2018, The Journal of allergy and clinical immunology.

[21]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[22]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[23]  I. Pavord,et al.  Blood eosinophil levels as a biomarker in COPD. , 2018, Respiratory medicine.

[24]  H. Ortega,et al.  Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma. , 2018, The journal of allergy and clinical immunology. In practice.

[25]  E. Hoffman,et al.  Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction , 2018, The Journal of clinical investigation.

[26]  E. Israel,et al.  Severe and Difficult‐to‐Treat Asthma in Adults , 2017, The New England journal of medicine.

[27]  W. Busse,et al.  Asthma Exacerbations: Pathogenesis, Prevention, and Treatment , 2017, The Journal of Allergy and Clinical Immunology: In Practice.

[28]  W. Busse.  A role for neutrophils in asthma exacerbations , 2017, Nature Medicine.

[29]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[30]  S. Johnston,et al.  Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation , 2017, Nature Medicine.

[31]  E. Bleecker,et al.  Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations , 2016, American journal of respiratory and critical care medicine.

[32]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[33]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[34]  Christopher E Brightling,et al.  Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. , 2016, The Lancet. Respiratory medicine.

[35]  Mike Thomas,et al.  Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. , 2015, The Lancet. Respiratory medicine.

[36]  Ayaka Tanaka,et al.  Progression of Irreversible Airflow Limitation in Asthma: Correlation with Severe Exacerbations. , 2015, The journal of allergy and clinical immunology. In practice.

[37]  J. Soriano,et al.  Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. , 2015, The New England journal of medicine.

[38]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[39]  N. Papadopoulos,et al.  IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. , 2014, American journal of respiratory and critical care medicine.

[40]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[41]  I. Pavord,et al.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.

[42]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[43]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[44]  R. Gangnon,et al.  Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. , 2012, The Journal of allergy and clinical immunology.

[45]  E. Bleecker,et al.  Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. , 2012, The Journal of allergy and clinical immunology.

[46]  M. Gill,et al.  Counterregulation between the FcεRI Pathway and Antiviral Responses in Human Plasmacytoid Dendritic Cells , 2010, The Journal of Immunology.

[47]  Rosalind J Wright,et al.  The Urban Environment and Childhood Asthma (URECA) birth cohort study: design, methods, and study population , 2009, BMC pulmonary medicine.

[48]  William W Busse,et al.  Severe exacerbations and decline in lung function in asthma. , 2009, American journal of respiratory and critical care medicine.

[49]  D. Postma,et al.  Severe exacerbations predict excess lung function decline in asthma , 2007, European Respiratory Journal.

[50]  S. Johnston,et al.  Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus , 2005, The Journal of experimental medicine.

[51]  R. Pauwels,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.

[52]  William W Busse,et al.  Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial , 2003, The Lancet.